Normalized LST is an efficient biomarker for homologous recombination deficiency and Olaparib response in ovarian carcinoma – Supplementary Figures

Yann Christinat¹, Liza Ho¹, Sophie Clément², Catherine Genestie³, Jalid Sehouli⁴, Antonio Gonzalez Martin⁵, Ursula Denison⁶, Keiichi Fujiwara⁷, Ignace Vergote⁸, Germana Tognon⁹, Sakari Hietanen¹⁰, Isabelle Ray-Coquard¹¹, Eric Pujade-Lauraine¹², Thomas A. McKee¹

Figure S1. Normalized LST score distribution according to different methods and the number of WGD events as given by the ABSOLUTE software. A) Ploidy-based method with k=3.5. B) Ploidy-based method with k=15.5. C) Method based on the average copy number. D) WGD-based method.

Figure S2. Distribution of nLST scores with respect to the tumor content as estimated by the Oncoscan analysis software.
Figure S3. Distribution for the nLST score and Myriad GIS on 405 patients from the PAOLA-1 trial and their paired comparison.

Figure S4. Kaplan-Meier plot of a three-way classification of the Myriad GIS score, with thresholds at 33 and 42, in the BRCA wild-type population upon A) Olaparib+Bevacizumab and B) Placebo+Bevacizumab treatment.